CN103432163A - 一种醋酸林格注射液及其制备方法 - Google Patents
一种醋酸林格注射液及其制备方法 Download PDFInfo
- Publication number
- CN103432163A CN103432163A CN2013103998049A CN201310399804A CN103432163A CN 103432163 A CN103432163 A CN 103432163A CN 2013103998049 A CN2013103998049 A CN 2013103998049A CN 201310399804 A CN201310399804 A CN 201310399804A CN 103432163 A CN103432163 A CN 103432163A
- Authority
- CN
- China
- Prior art keywords
- injection
- water
- room temperature
- weight
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000008156 Ringer's lactate solution Substances 0.000 title claims abstract description 26
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 title claims abstract description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 73
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 40
- 239000000243 solution Substances 0.000 claims abstract description 33
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims abstract description 20
- 229940040526 anhydrous sodium acetate Drugs 0.000 claims abstract description 20
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims abstract description 20
- 229940052299 calcium chloride dihydrate Drugs 0.000 claims abstract description 20
- 239000001103 potassium chloride Substances 0.000 claims abstract description 20
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 20
- 239000011780 sodium chloride Substances 0.000 claims abstract description 20
- 238000002347 injection Methods 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 18
- 238000003756 stirring Methods 0.000 claims abstract description 18
- 230000001954 sterilising effect Effects 0.000 claims abstract description 17
- 238000003556 assay Methods 0.000 claims abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 69
- 239000008215 water for injection Substances 0.000 claims description 62
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 48
- 238000010792 warming Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 238000012856 packing Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 abstract 2
- 238000010438 heat treatment Methods 0.000 abstract 2
- 238000009413 insulation Methods 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 239000000047 product Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310399804.9A CN103432163B (zh) | 2013-09-05 | 2013-09-05 | 一种醋酸林格注射液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310399804.9A CN103432163B (zh) | 2013-09-05 | 2013-09-05 | 一种醋酸林格注射液及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103432163A true CN103432163A (zh) | 2013-12-11 |
CN103432163B CN103432163B (zh) | 2015-06-17 |
Family
ID=49685949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310399804.9A Expired - Fee Related CN103432163B (zh) | 2013-09-05 | 2013-09-05 | 一种醋酸林格注射液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103432163B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111450053A (zh) * | 2020-04-28 | 2020-07-28 | 山西省芮城县红宝兽药有限责任公司 | 一种具有较高稳定性及活性的黄芪多糖注射液的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972257A (zh) * | 2010-09-10 | 2011-02-16 | 杭州民生药业有限公司 | 一种含有莫西沙星的药物组合物 |
CN102293780A (zh) * | 2011-08-16 | 2011-12-28 | 湖北博瑞佳医药科技有限公司 | 一种醋酸钠林格注射液及其制备方法 |
-
2013
- 2013-09-05 CN CN201310399804.9A patent/CN103432163B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101972257A (zh) * | 2010-09-10 | 2011-02-16 | 杭州民生药业有限公司 | 一种含有莫西沙星的药物组合物 |
CN102293780A (zh) * | 2011-08-16 | 2011-12-28 | 湖北博瑞佳医药科技有限公司 | 一种醋酸钠林格注射液及其制备方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111450053A (zh) * | 2020-04-28 | 2020-07-28 | 山西省芮城县红宝兽药有限责任公司 | 一种具有较高稳定性及活性的黄芪多糖注射液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103432163B (zh) | 2015-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104530263A (zh) | 一种没食子酸蔗渣木聚糖酯的制备方法 | |
CN102988291A (zh) | 一种氟比洛芬酯脂肪乳注射液组合物及其制备方法 | |
CN104586758B (zh) | 一种对乙酰氨基酚注射液及其制备方法 | |
CN102419352A (zh) | 一种邻苯二甲酸酯类物质总量的测定方法 | |
CN104013571A (zh) | 一种奥硝唑注射液及其制备方法 | |
AU2022313274B2 (en) | Microcapsule powder stable in gastric acid, preparation method therefor and application thereof | |
CN103432163A (zh) | 一种醋酸林格注射液及其制备方法 | |
CN106645481B (zh) | 一种测试速释剂型药物阿莫西林克拉维酸钾分散片的溶出曲线的方法 | |
CN108295333A (zh) | 一种一次性输液器 | |
CN103655500B (zh) | 一种维生素c片及其制备方法 | |
CN103520103A (zh) | 一种维生素e纳米乳及其制备方法 | |
CN103463614B (zh) | 一种阿加曲班注射液及其制备方法 | |
CN101980012A (zh) | 水产品中氨苄青霉素和阿莫西林残留量的高效液相色谱荧光检测法 | |
CN104820026A (zh) | 一种荔枝核滴丸质量检测方法 | |
CN102335124A (zh) | 蒿甲醚注射液及其制剂工艺 | |
CN102344360B (zh) | 精氨酸右旋布洛芬的制备方法 | |
CN102579332A (zh) | 一种布洛芬注射液的制备方法 | |
CN103720741A (zh) | 一种中长链脂肪乳/氨基酸(16)/葡萄糖(16%)注射用组合物 | |
CN103804366B (zh) | 一种拉呋替丁晶型化合物 | |
CN103830171B (zh) | 一种酮咯酸氨丁三醇注射液及其制备方法 | |
CN102370996A (zh) | 一种浓缩超声导电胶及其制备和使用方法 | |
CN102120026A (zh) | 以醇作为增溶剂的21(s)阿加曲班静脉注射液 | |
CN106176595A (zh) | 一种更昔洛韦注射液及其制备工艺 | |
CN102824340A (zh) | 布洛芬组合物注射液及其制备方法 | |
CN105467071B (zh) | 一种胶体果胶铋药物组合物的质量控制及其半乳糖醛酸含量的测定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160406 Address after: 200437 Shanghai city Yangpu District Yixian Road No. 25 room 1103/1105 Patentee after: Shanghai King King pharmaceutical science and Technology Development Co Ltd Address before: 200042 Shanghai City, Changning District Changning Road No. 398 Mega building 16A Patentee before: Wang Jiehua Patentee before: Wang Yaowu |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150617 Termination date: 20170905 |